TY  -  JOUR
AU  -  Sabatucci, Ilaria
AU  -  Lorusso, Domenica
T1  -  The role of niraparib in the treatment of ovarian cancer: 
actuality and perspectives
PY  -  2017
Y1  -  2017-06-01
DO  -  10.1701/2715.27713
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  108
IS  -  6
SP  -  265
EP  -  268
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/18
UR  -  http://dx.doi.org/10.1701/2715.27713
N2  -  Summary. PARP inhibitors interfere with single-strand DNA damage repair determining a progression of the defect in double-stranded breaks. About 50% of high-grade serous ovarian cancer patients presents deficient pathways of homologous recombination, involved on double-strand DNA damage repair. The inability to repair double-strand damage determines cell death, a process defined “synthetic lethality”. Among the PARP inhibitors family, niraparib is the first one approved by FDA for the treatment of ovarian cancer patients, regardless of the presence or absence of gBRCA mutations. The label was obtained thanks to data of phase III ENGOT-OV16/NOVA trial, reporting an increased progression-free survival with a good toxicity profile for the drug. Further clinical trials are ongoing to evaluate extended indications on the use of niraparib for the treatment of ovarian cancer.
ER  -